ATE243501T1 - Zubereitung mit gesteuerter freisetzung - Google Patents

Zubereitung mit gesteuerter freisetzung

Info

Publication number
ATE243501T1
ATE243501T1 AT95900570T AT95900570T ATE243501T1 AT E243501 T1 ATE243501 T1 AT E243501T1 AT 95900570 T AT95900570 T AT 95900570T AT 95900570 T AT95900570 T AT 95900570T AT E243501 T1 ATE243501 T1 AT E243501T1
Authority
AT
Austria
Prior art keywords
pct
active compound
polymer matrix
controlled release
release preparation
Prior art date
Application number
AT95900570T
Other languages
English (en)
Inventor
Yan Chen
Bruce Nathaniel Gray
Original Assignee
Sirtex Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3777364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE243501(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sirtex Medical Ltd filed Critical Sirtex Medical Ltd
Application granted granted Critical
Publication of ATE243501T1 publication Critical patent/ATE243501T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT95900570T 1993-11-18 1994-11-17 Zubereitung mit gesteuerter freisetzung ATE243501T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPM249293 1993-11-18
PCT/AU1994/000708 WO1995013798A1 (en) 1993-11-18 1994-11-17 Controlled release preparation

Publications (1)

Publication Number Publication Date
ATE243501T1 true ATE243501T1 (de) 2003-07-15

Family

ID=3777364

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95900570T ATE243501T1 (de) 1993-11-18 1994-11-17 Zubereitung mit gesteuerter freisetzung

Country Status (9)

Country Link
US (1) US5932248A (de)
EP (1) EP0727984B1 (de)
JP (1) JP4619457B2 (de)
CN (1) CN1139380A (de)
AT (1) ATE243501T1 (de)
AU (1) AU693821B2 (de)
CA (1) CA2176933A1 (de)
DE (1) DE69432867T2 (de)
WO (1) WO1995013798A1 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2775435B1 (fr) * 1998-02-27 2000-05-26 Bioalliance Pharma Nanoparticules comprenant au moins un polymere et au moins un compose apte a complexer un ou plusieurs principes actifs
WO1999049908A1 (en) 1998-03-31 1999-10-07 University Of Cincinnati Temperature controlled solute delivery system
CA2248592A1 (en) 1998-08-31 2000-02-29 Christopher D. Batich Microspheres for use in the treatment of cancer
KR100845769B1 (ko) 1999-02-03 2008-07-11 파우더젝트 리서치 리미티드 하이드로겔 입자 제제
EP1158961A1 (de) * 1999-03-08 2001-12-05 PowderJect Research Limited Verabreichung von mikroteilchen-formulierungen unter verwendung einer nadellosen spritze zur verzörgerten freigabe bioaktiver verbindungen
JP2003524624A (ja) * 1999-04-09 2003-08-19 ジェシー エル エス オウ 治療薬の組織への送達を高める方法及び組成物
JP2001031577A (ja) * 1999-07-16 2001-02-06 Fujibio Co Ltd キチン・キトサンによるシスプラチンの副作用防止方法及びそのための配合剤
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US20030206958A1 (en) * 2000-12-22 2003-11-06 Cattaneo Maurizio V. Chitosan biopolymer for the topical delivery of active agents
US20030212022A1 (en) * 2001-03-23 2003-11-13 Jean-Marie Vogel Compositions and methods for gene therapy
DE01918975T1 (de) 2000-03-24 2006-04-13 Biosphere Medical, Inc., Rockland Mikrokügelchen zur aktiven Embolisierung
AUPR098300A0 (en) * 2000-10-25 2000-11-16 Sirtex Medical Limited Polymer based radionuclide containing microspheres
ATE430558T1 (de) 2000-10-27 2009-05-15 Baxter Healthcare Sa Herstellung von mikrokügelchen
DK1355566T3 (da) * 2000-12-18 2013-03-04 Univ Texas Lokal regional kemoterapi og radioterapi ved anvendelse af hydrogel in situ
US20080026068A1 (en) * 2001-08-16 2008-01-31 Baxter Healthcare S.A. Pulmonary delivery of spherical insulin microparticles
US20030064033A1 (en) * 2001-08-16 2003-04-03 Brown Larry R. Propellant-based microparticle formulations
EP1429728A1 (de) * 2001-08-29 2004-06-23 SRL Technologies, Inc. Zubereitungen mit verzögerter freisetzung
US8425892B2 (en) * 2001-10-29 2013-04-23 Columbia Laboratories, Inc. Extended, controlled-release pharmaceutical compositions using charged polymers
US8685427B2 (en) * 2002-07-31 2014-04-01 Boston Scientific Scimed, Inc. Controlled drug delivery
US8133501B2 (en) 2002-02-08 2012-03-13 Boston Scientific Scimed, Inc. Implantable or insertable medical devices for controlled drug delivery
US8920826B2 (en) 2002-07-31 2014-12-30 Boston Scientific Scimed, Inc. Medical imaging reference devices
US20040161466A1 (en) 2003-02-14 2004-08-19 Biocompatibles Uk Limited Chemoembolisation
HK1079980B (en) * 2003-02-12 2008-11-14 Biocompatibles Uk Limited Composition for chemoembolotherapy of solid tumors
CN1747721A (zh) * 2003-02-12 2006-03-15 生物相容英国有限公司 用于实体瘤的化学栓塞治疗的组合物
US20070092452A1 (en) * 2003-07-18 2007-04-26 Julia Rashba-Step Methods for fabrication, uses, compositions of inhalable spherical particles
US20050142205A1 (en) * 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
BRPI0412735A (pt) * 2003-07-18 2006-09-26 Baxter Int métodos para a fabricação, uso e composição de partìculas esféricas pequenas preparadas mediante a separação de fase controlada
JP2007508240A (ja) * 2003-07-22 2007-04-05 バクスター・インターナショナル・インコーポレイテッド 低分子量有機分子の小球状粒子ならびにその調製方法および使用方法
WO2005087193A2 (en) * 2004-03-11 2005-09-22 Biocompatibles Uk Limited Chemoembolisation involving an anthracycline compound
AU2005240189A1 (en) * 2004-05-06 2005-11-17 Ivrea Pharmaceuticals, Inc. Particles for the delivery of active agents
US20060141046A1 (en) * 2004-05-06 2006-06-29 Ivrea Pharmaceuticals, Inc. Particles for the delivery of active agents
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
MXPA06012992A (es) 2004-05-12 2007-02-12 Baxter Int Microesferas que comprenden proteina y que muestran inyectabilidad en altas concentraciones de este agente.
CA2566199C (en) * 2004-05-12 2013-10-22 Baxter International Inc. Delivery of as-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes
EP1765294B1 (de) 2004-05-12 2008-09-24 Baxter International Inc. Nukleinsäure-mikrokügelchen, ihre herstellung und abgabe
US20050265955A1 (en) * 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
WO2006002365A2 (en) * 2004-06-24 2006-01-05 Angiotech International Ag Microparticles with high loadings of a bioactive agent
EP1885335A1 (de) * 2005-04-27 2008-02-13 BAXTER INTERNATIONAL INC. (a Delaware corporation) Oberflächenmodifizierte mikroteilchen und verfahren zu ihrer bildung und verwendung
KR20140090270A (ko) 2005-05-09 2014-07-16 바이오스피어 메디칼 에스.에이. 마이크로스피어 및 비이온성 조영제를 사용하는 조성물 및 방법
US8343546B2 (en) * 2005-09-13 2013-01-01 Coating Place, Inc. Ion exchange resin treated to control swelling
WO2007109274A2 (en) * 2006-03-21 2007-09-27 Alza Corporation Hydratable polymeric ester matrix for drug electrotransport
US20070281031A1 (en) * 2006-06-01 2007-12-06 Guohan Yang Microparticles and methods for production thereof
CN101500616A (zh) 2006-08-04 2009-08-05 巴克斯特国际公司 预防和/或逆转新发作自身免疫糖尿病的基于微球的组合物
CZ299053B6 (cs) * 2006-08-09 2008-04-09 Zentiva, A. S. Polymerní konjugáty doxorubicinu s pH-rízeným uvolnováním léciva a zpusob jejich prípravy
CZ2006592A3 (cs) * 2006-09-18 2008-03-19 Zentiva, A. S. Polymerní lécivo a zpusob jeho výroby
WO2008060786A2 (en) * 2006-10-06 2008-05-22 Baxter International Inc. Microencapsules containing surface-modified microparticles and methods of forming and using the same
WO2008075173A2 (en) * 2006-12-15 2008-06-26 Ruprecht-Karls-Universität Heidelberg Methods for treating podocyte-related disorders
HUE035243T2 (hu) * 2007-02-23 2018-05-02 Sk Chemicals Co Ltd Eljárás VIII. faktor és származékainak elõállítására és tisztítására
US8568777B2 (en) * 2007-03-30 2013-10-29 Monosol Rx, Llc Packaged film dosage unit containing a complexate
JP2008120838A (ja) * 2008-02-21 2008-05-29 Medgel Corp 配位結合を利用した薬物−高分子複合体製剤の調製方法
US8367427B2 (en) * 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles
US20100047292A1 (en) * 2008-08-20 2010-02-25 Baxter International Inc. Methods of processing microparticles and compositions produced thereby
US8323685B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
US8323615B2 (en) * 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
US8540667B2 (en) * 2008-11-12 2013-09-24 Sanovas, Inc. Multi-balloon catheter for extravasated drug delivery
US8226601B2 (en) 2008-11-12 2012-07-24 Sanovas, Inc. Resector balloon system
US20160074581A1 (en) 2014-09-17 2016-03-17 Lawrence J. Gerrans Modulated Drug Delivery
US8597239B2 (en) * 2011-03-01 2013-12-03 Sanovas, Inc. Abrading balloon catheter for extravasated drug delivery
AU2012222833B2 (en) 2011-03-03 2017-03-16 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
TWI568453B (zh) * 2011-11-22 2017-02-01 原創生醫股份有限公司 具有螯合型複合微胞之藥物載體及其應用
HRP20171364T1 (hr) * 2012-11-15 2017-11-03 Utah-Inha Dds & Advanced Therapeutics Research Center Biorazgradive mikrogranule s poboljšanim kapacitetom adsorpcije lijekova protiv raka, koji sadržava albumin i dekstran sulfat, i postupak njihove pripreme
EP2926806B1 (de) * 2012-11-27 2019-07-03 Utah-Inha DDS & Advanced Therapeutics Research Center Biologisch abbaubare mikrokügelchen mit einem anionischen polymer zur verbesserung adsorptionskraft an krebsmedikamente und verfahren zur herstellung davon
WO2014152790A1 (en) * 2013-03-14 2014-09-25 Drexel University Chelated drug delivery systems
US9839617B2 (en) * 2014-01-27 2017-12-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Nanoencapsulation of hydrophilic active compounds
KR101614911B1 (ko) * 2014-05-14 2016-04-25 재단법인 유타 인하 디디에스 및 신의료기술개발 공동연구소 제 1 및 제 2 생분해성 마이크로 비드를 포함하는 화학색전용 조성물 및 이의 제조방법
CN105125522B (zh) * 2015-09-05 2018-08-21 四川大学 一种透明质酸-阳离子药物离子对微粒
US11246945B2 (en) * 2019-06-07 2022-02-15 National Defense Medical Center Cisplatin-loaded microbubbles, pharmaceutical composition for treatment of cancer, method for preparing pharmaceutical compositions and method for treating cancer
CN114947108A (zh) * 2022-04-28 2022-08-30 中国农业大学 酪蛋白胶束精准控释组合物及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4671954A (en) * 1983-12-13 1987-06-09 University Of Florida Microspheres for incorporation of therapeutic substances and methods of preparation thereof
FR2585246A1 (fr) * 1985-07-26 1987-01-30 Cortial Procede d'obtention de formes pharmaceutiques solides a liberation prolongee
US4946686A (en) * 1987-09-24 1990-08-07 Merck & Co., Inc. Solubility modulated drug delivery system
US5100668A (en) * 1988-06-14 1992-03-31 Massachusetts Institute Of Technology Controlled release systems containing heparin and growth factors
US5271945A (en) * 1988-07-05 1993-12-21 Takeda Chemical Industries, Ltd. Sustained release microcapsule for water soluble drug
US4996047A (en) * 1988-11-02 1991-02-26 Richardson-Vicks, Inc. Sustained release drug-resin complexes
CA2014244A1 (en) * 1989-04-13 1990-10-13 Takeda Chemical Industries, Ltd. Stabilized composition of anthracyclines
US5288496A (en) * 1990-05-15 1994-02-22 Stolle Research & Development Corporation Growth promoters for animals
EP0563294A1 (de) * 1990-12-21 1993-10-06 Richardson-Vicks, Inc. Polyaminwirkstoffharzkomplexe
AU653771B2 (en) * 1991-01-03 1994-10-13 Alkermes Controlled Therapeutics, Inc. Stabilization of proteins by cationic biopolymers
DE69311538D1 (de) * 1992-03-12 1997-07-17 Alkermes Inc Acth enthaltende mikrokugeln mit gesteuerter abgabe

Also Published As

Publication number Publication date
CN1139380A (zh) 1997-01-01
DE69432867D1 (de) 2003-07-31
JP4619457B2 (ja) 2011-01-26
WO1995013798A1 (en) 1995-05-26
US5932248A (en) 1999-08-03
EP0727984B1 (de) 2003-06-25
CA2176933A1 (en) 1995-05-26
AU693821B2 (en) 1998-07-09
DE69432867T2 (de) 2004-04-22
EP0727984A4 (de) 1997-09-10
JPH09505059A (ja) 1997-05-20
EP0727984A1 (de) 1996-08-28
AU8136394A (en) 1995-06-06

Similar Documents

Publication Publication Date Title
ATE243501T1 (de) Zubereitung mit gesteuerter freisetzung
GB9310412D0 (en) Nasal nicotine system
MX9304975A (es) Una composicion en polvo para inhalacion y procedimiento para preparar la misma.
AU6421594A (en) High release solid preparation, preparation and use thereof
AU5106996A (en) Process for producing active agent preparations in the form of a solid solution of the active agent in a polymer matrix and active agent preparations obtained thereby
AU5680100A (en) Controlled release and taste masking oral pharmaceutical compositions
RU95108318A (ru) Композиция, состоящая из дендримера и активного вещества, заключенного в дендримере, способ получения такой композиции и способ высвобождения активного вещества
CA2225808A1 (en) Silver-based pharmaceutical compositions
DE3583799D1 (de) Feste zubereitung mit langsamer freisetzung.
BG105568A (en) Pharmaceutical compositions for modified release of an insulin sensitiser and another antidiabetic agent
AU1884497A (en) New associations of active principles containing clopidogrel and an antithrombotic agent
ATE269709T1 (de) Tablette mit verzögerter freigabe enthaltend einen blutzuckersenkenden wirkstoff und einen antihyperglyzemischen wirkstoff
ES2115638T3 (es) Composicion tiroactiva de liberacion controlada.
CA2409292A1 (en) Tablets and methods for modified release of hydrophilic and other active agents
CA2067228A1 (en) Drug delivery system, method for preparing the same and use thereof
CA2039053A1 (en) Material for adsorbing pyrogen
CA2340898A1 (en) Compositions and methods for treating intracellular infections
IT1274241B (it) Complessi agente terapeutico/matrice polimerica dotati di migliorate caratteristiche di sapore e composizioni farmaceutiche che li contengono
WO1999061010A3 (en) Treatment of infertility with cam-increasing compounds alone or in combination with at least one meiosis-stimulating compound
BR9307193A (pt) Processo para a preparação de uma formulação sólida de um agente de proteção de culturas e formulação sólida de agente de proteção de culturas
FI963567A0 (fi) Diklofenakki-Na:a sisältävä depottabletti
CA2273272A1 (en) Immediate release drug delivery forms
ATE364403T1 (de) Retardtablette hergestellt aus linearen wasserunlöslichen polysacchariden
DE59510583D1 (de) Pharmazeutische zusammensetzung zur systemischen transdermalen verabreichung mit dem wirkstoff morphin-6-glucuronid
RU95101840A (ru) Сложные эфиры циклогексанола и содержащий их фармацевтический препарат

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties